Comparison of daily versus alternate day high dose chemotherapy (cytarabine) in acute myeloid leukemia patients in consolidation phase.

Comparision of consecutive versus alternate day schedules of high-dose cytarabine consolidation chemotherapy in acute myeloid leukemia patients: A randomised pilot study - nil

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/02/081494

Enrollment

Registered

2025-02-28

Start date

Unknown

Completion date

Unknown

Last updated

2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C920- Acute myeloblastic leukemia

Interventions

Intervention1: High dose cytarabine(1.5gm/m2): Injection Cytarabine 1.5 Gm/m2 in 500 ml NS(0.9%) over three hours twice daily for three consecutive days. Control Intervention1: High dose cytarabine (1

Eligibility

Inclusion criteria

Inclusion criteria: Newly diagnosed acute myeloid leukemia patients

Exclusion criteria

Exclusion criteria: Acute promyelocytic leukemia. Secondary AML. Patients with concomitant renal dysfunction. Patients with liver dysfunction. Patients with cardiac dysfunction Patients with uncontrolled infection. Performance status Eastern Cooperative Oncology Group more than two Pregnant AML patients. Patients who have received any multiagent chemotherapy other than HiDAC as post-remission treatment. Primary refractory AML

Design outcomes

Primary

Measure	Time frame
To compare the consecutive versus alternative day schedules of HiDAC chemotherapy in terms of treatment outcome. To compare the consecutive vs alternative day schedules of HiDAC chemotherapy in terms of toxicity. Timepoint: Day 21- Day 28 post Hidac chemotherapy as per hematological count recovery	—

Secondary

Measure	Time frame
nilTimepoint: nil	—

Countries

India

Contacts

Public ContactRONANKI KAVYA

All India Institute Of Medical Sciences (AIIMS )RISHIKESH

uttam.monc@aiimsrishikesh.edu.in9433982756

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026